LiteOdyssey: A Lightweight Reasoning AI Agent for Interpretable Rare-Disease Diagnosis

• URL: http://arxiv.org/abs/2606.16149v1
• Date: Mon, 15 Jun 2026 03:10:17 GMT
• Title: LiteOdyssey: A Lightweight Reasoning AI Agent for Interpretable Rare-Disease Diagnosis
• Abstract summary: LiteOdyssey is a lightweight rare-disease diagnostic framework that guides reasoning language model through a clinical genetics workflow.<n> LiteOdyssey achieved state-of-the-art performance, with an overall disease Recall@1 of 59.3% over the combined 1,243 cases of LIRICAL and the PhenoPacket Store.<n> LiteOdyssey suggests a path toward rare-disease AI systems that are accurate, easier to deploy, and more transparent for physician review.
• Score: 5.485944483858884
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Most medical AI systems improve by scaling additional machinery: more fine-tuning data, more agents, and/or larger retrieval databases. In rare-disease diagnosis, however, such scaling can produce systems that are difficult to deploy, audit, and maintain. We asked whether state-of-the-art diagnostic performance could instead be achieved by extending the reasoning chain of a single AI agent: guiding it with a diagnostic policy, developed through human-AI collaboration and augmenting with freely available biomedical tools. We introduce LiteOdyssey, a lightweight rare-disease diagnostic framework that guides reasoning language model through a clinical genetics workflow. This framework was developed through Policy Iteration with Human Feedback (PIHF) and uses dynamic access to public biomedical tools. On two challenging benchmarks that provide only patient clinical features, LiteOdyssey achieved state-of-the-art performance, with an overall disease Recall@1 of 59.3% over the combined 1,243 cases of LIRICAL (n = 370) and the PhenoPacket Store (n = 873). Both benchmarks have a high proportion of ultra-rare disease (a prevalence below 1 in 1,000,000, with ultra-rare shares of approximately 45% and 52.8%, respectively). On the more difficult PhenoPacket subset, where causal diseases were not mapped to Orphanet in our rarity-mapping pipeline, LiteOdyssey achieved 60.7% Recall@1, compared with 10.7% for the same baseline model (GPT-5.4) without tools. This performance was achieved without fine-tuning, multi-agent ensembles, or a large case-retrieval database. Gains were also observed in the following: on cases never seen during development, on a private cohort of real-world rare disease patients, and on a smaller open-weights model. LiteOdyssey suggests a path toward rare-disease AI systems that are accurate, easier to deploy, and more transparent for physician review.

Related papers

• Auditable agentic AI for evidence-grounded thyroid ultrasound diagnosis and reporting [59.709162055944915]
  ThyroidXAgent is an agentic AI system that coordinates specialized diagnostic tools and stores their outputs as an auditable case-level evidence record.<n>It was evaluated on 28,458 non-overlapping test cases, including 8,721 cases from 35 centres in the private NHC-MISD-TUS cohort.<n>It achieved a mean Dice score of 87.21 percent for segmentation and a mean AUROC of 0.9466 for benign-malignant classification.
  arXiv  Detail & Related papers  (2026-08-12T21:02:59Z)
• RareLens: Towards End-to-End Rare Disease Care via Aligning Divergent Large Language Model Reasoning [42.80742579670377]
  RareLens is a system that supports clinical decision-making across the entire rare disease trajectory.<n>Developed and evaluated on RareBench, a real-world dataset of 157,525 cases spanning all 33 Orphanet categories and more than 7,000 conditions.<n>It achieved an area under the curve of 0.917 for screening and top-1 accuracies of 65.5% and 89.8% for diagnosis and treatment.
  arXiv  Detail & Related papers  (2026-07-25T16:58:10Z)
• Eliciting Medical Reasoning with Knowledge-enhanced Data Synthesis: A Semi-Supervised Reinforcement Learning Approach [62.0906177191353]
  Existing approaches distill chain-of-thought reasoning traces from large proprietary models via supervised fine-tuning, then conduct reinforcement learning (RL)<n>We propose MedSSR, a Medical Knowledge-enhanced data Synthesis and Semi-supervised Reinforcement learning framework.<n>Our framework first employs rare disease knowledge to synthesize distribution-controllable reasoning questions.<n>We then utilize the policy model itself to generate high-quality pseudo-labels. This enables a two-stage, intrinsic-to-extrinsic training paradigm: self-supervised RL on the pseudo-labeled data, followed by supervised RL on the human-annotated real data
  arXiv  Detail & Related papers  (2026-04-13T14:37:38Z)
• A DeepSeek-Powered AI System for Automated Chest Radiograph Interpretation in Clinical Practice [83.11942224668127]
  Janus-Pro-CXR (1B) is a chest X-ray interpretation system based on DeepSeek Janus-Pro model.<n>Our system outperforms state-of-the-art X-ray report generation models in automated report generation.
  arXiv  Detail & Related papers  (2025-12-23T13:26:13Z)
• An Explainable Hybrid AI Framework for Enhanced Tuberculosis and Symptom Detection [55.35661671061754]
  Tuberculosis remains a critical global health issue, particularly in resource-limited and remote areas.<n>We propose a framework which enhances disease and symptom detection on chest X-rays by integrating two supervised heads and a self-supervised head.<n>Our model achieves an accuracy of 98.85% for distinguishing between COVID-19, tuberculosis, and normal cases, and a macro-F1 score of 90.09% for multilabel symptom detection.
  arXiv  Detail & Related papers  (2025-10-21T17:18:55Z)
• Design and Validation of a Responsible Artificial Intelligence-based System for the Referral of Diabetic Retinopathy Patients [65.57160385098935]
  Early detection of Diabetic Retinopathy can reduce the risk of vision loss by up to 95%.<n>We developed RAIS-DR, a Responsible AI System for DR screening that incorporates ethical principles across the AI lifecycle.<n>We evaluated RAIS-DR against the FDA-approved EyeArt system on a local dataset of 1,046 patients, unseen by both systems.
  arXiv  Detail & Related papers  (2025-08-17T21:54:11Z)
• Toward the Autonomous AI Doctor: Quantitative Benchmarking of an Autonomous Agentic AI Versus Board-Certified Clinicians in a Real World Setting [0.0]
  Globally we face a projected shortage of 11 million healthcare practitioners by 2030.<n>No end-to-end autonomous large language model (LLM)-based AI system has been rigorously evaluated in real-world clinical practice.
  arXiv  Detail & Related papers  (2025-06-27T19:04:44Z)
• An Agentic System for Rare Disease Diagnosis with Traceable Reasoning [69.46279475491164]
  We introduce DeepRare, the first rare disease diagnosis agentic system powered by a large language model (LLM)<n>DeepRare generates ranked diagnostic hypotheses for rare diseases, each accompanied by a transparent chain of reasoning.<n>The system demonstrates exceptional diagnostic performance among 2,919 diseases, achieving 100% accuracy for 1013 diseases.
  arXiv  Detail & Related papers  (2025-06-25T13:42:26Z)
• Artificial Intelligence-Based Triaging of Cutaneous Melanocytic Lesions [0.8864540224289991]
  Pathologists are facing an increasing workload due to a growing volume of cases and the need for more comprehensive diagnoses. We developed an artificial intelligence (AI) model for triaging cutaneous melanocytic lesions based on whole slide images.
  arXiv  Detail & Related papers  (2024-10-14T13:49:04Z)
• A Concept-based Interpretable Model for the Diagnosis of Choroid Neoplasias using Multimodal Data [28.632437578685842]
  We focus on choroid neoplasias, the most prevalent form of eye cancer in adults, albeit rare with 5.1 per million. Our work introduces a concept-based interpretable model that distinguishes between three types of choroidal tumors, integrating insights from domain experts via radiological reports. Remarkably, this model achieves an F1 score of 0.91, rivaling that of black-box models, but also boosts the diagnostic accuracy of junior doctors by 42%.
  arXiv  Detail & Related papers  (2024-03-08T07:15:53Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.